<DOC>
	<DOC>NCT01304147</DOC>
	<brief_summary>The objective of the current study is to investigate the safety and efficacy of a single dose of intranasal (IN) ketamine in treatment-resistant depression (TRD).</brief_summary>
	<brief_title>Intranasal Ketamine in Treatment-Resistant Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>1. Male or female patients, 2165 years; 2. Women of childbearing potential must agree to use a medically accepted means of contraception for the duration of the study; 3. Primary diagnosis of major depressive disorder as assessed by the SCIDP; 4. Current depressive episode; 5. History of a failure to respond to at least one (1) adequate pharmacotherapy trials in the current major depressive episode; 6. Subjects must have scored ≥ 30 on the IDSC30 at Screening ≥ 24 at Treatment Day #1 and #2; 7. Each subject must have a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign an informed consent document; 8. Subjects must be able to identify a family member, physician, or friend who will participate in the Treatment Contract and serve as an emergency contact. 1. Women who plan to become pregnant, are pregnant or are breastfeeding; 2. Any unstable medical illness including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease; 3. Clinically significant abnormal findings of laboratory parameters, physical examination, or ECG; 4. Lifetime history of schizophrenia, schizoaffective disorder, bipolar disorder, OCD, mental retardation, pervasive developmental disorders, or Tourette's syndrome; 5. Drug or alcohol abuse or dependence within the preceding 6 months; 6. Lifetime abuse or dependence on ketamine or phencyclidine; 7. Patients judged by study investigator to be at high risk for suicide. 8. Previous participation in a ketamine study at Mount Sinai</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ketamine</keyword>
	<keyword>depression</keyword>
	<keyword>treatment resistance</keyword>
	<keyword>intranasal, antidepressant</keyword>
	<keyword>glutamate</keyword>
	<keyword>NMDA receptor</keyword>
</DOC>